EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)
Post hoc analysis of Phase 2 FILLY study shows 39% reduction in rate of progression from nascent GA, an earlier form of disease, to GA in patients treated with pegcetacoplan monthly vs. sham First ever observation of slowed nascent GA progression in a Phase 2
Epidarex Capital Co-leads $29 Million Series A Financing in Newly Formed Libra Therapeutics
Libra Therapeutics is developing novel therapeutics for neurodegenerative diseases BETHESDA, MD (US) and EDINBURGH (UK), September 23, 2020 – Epidarex Capital (“Epidarex”), a transatlantic life
Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002
ETD002 is a novel TMEM16A chloride channel potentiator Therapy applicable to all cystic fibrosis patients, independent of genotype Brighton, UK, 17 August 2020: Enterprise Therapeutics
Macomics, an immuno-oncology company, secures £3.2 million seed funding from Epidarex Capital & the Scottish Investment Bank
Novel immuno-therapies to overcome the resistance of existing cancer treatments Builds on the world-leading research into tumour associated macrophages (TAMs) Robert Haigh joins as CEO
Epidarex Capital Closes New £102 Million UK Venture Fund to Build Successful Life Science Companies
New UK fund cornerstoned by £50 million investment from the British Business Bank, through its Enterprise Capital Funds (ECF) programme Epidarex Capital III UK LP
SIRAKOSS Receives U.S. FDA 510(k) Clearance for Osteo3 ZP Putty to Catalyse Rapid and Complete Bone Regeneration
Combines Best-in-Class Bone Repair with Intraoperative Ease-of-Use for Spine and Trauma Bone Grafting Applications Aberdeen, UK, 17 June 2020 – SIRAKOSS Ltd, a developer of
New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH
71% of pegcetacoplan-treated patients achieved LDH normalization vs. 15% of eculizumab-treated patients 73% of pegcetacoplan-treated patients achieved a clinically meaningful improvement in FACIT-fatigue score vs.
NodThera Announces Close of $55 Million Series B Financing
Financing round led by Novo Ventures and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital,